Suppr超能文献

基因和诱导多能干细胞治疗视网膜疾病。

Gene and Induced Pluripotent Stem Cell Therapy for Retinal Diseases.

机构信息

Laboratory for Retinal Regeneration, Center for Biosystems Dynamics Research, RIKEN, Kobe, Hyogo 650-0047, Japan; email:

Kobe City Eye Center Hospital, Kobe, Hyogo 650-0047, Japan.

出版信息

Annu Rev Genomics Hum Genet. 2019 Aug 31;20:201-216. doi: 10.1146/annurev-genom-083118-015043. Epub 2019 Apr 24.

Abstract

Given the importance of visual information to many daily activities, retinal degenerative diseases-which include both inherited conditions (such as retinitis pigmentosa) and acquired conditions (such as age-related macular degeneration)-can have a dramatic impact on human lives. The therapeutic options for these diseases remain limited. Since the discovery of the first causal gene for retinitis pigmentosa almost three decades ago, more than 250 genes have been identified, and gene therapies have been rapidly developed. Simultaneously, stem cell technologies such as induced pluripotent stem cell-based transplantation have advanced and have been applied to the treatment of retinal degenerative diseases. Here, we review recent progress in these expanding fields and discuss the potential for precision medicine in ophthalmic care.

摘要

鉴于视觉信息对许多日常活动的重要性,视网膜退行性疾病——包括遗传性疾病(如色素性视网膜炎)和获得性疾病(如年龄相关性黄斑变性)——会对人类生活产生重大影响。这些疾病的治疗选择仍然有限。自三十年前发现第一个色素性视网膜炎的致病基因以来,已经鉴定出 250 多个基因,并且基因疗法也得到了迅速发展。与此同时,干细胞技术(如基于诱导多能干细胞的移植)也取得了进展,并已应用于治疗视网膜退行性疾病。在这里,我们回顾了这些不断发展的领域的最新进展,并讨论了眼科精准医疗的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验